0.5 mg Sirolimus Tablet Blister.jpg (0.5 mg Sirolimus Tablet Blister.jpg)
Sirolimus Tablet, Film Coated
Product Images NDC 60687-902
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Sirolimus (NDC 60687-902). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
0.5 mg Sirolimus Tablets Carton.jpg (0.5 mg Sirolimus Tablets Carton.jpg)
This is a description of Sirolimus Tablets with NDC 60687-902-21, intended for oral use only. Each tablet contains Sirolmus 0.5mg and color additives including FD&C Yellow No. 6. The usual dosage should be referred to in the full prescribing information. It should be stored at 20-25°C (68-77°F) with excursions permitted between 15-30°C (58-86°F). This medication is distributed by American Health Packaging from Zydus Pharmaceuticals (USA). Please check for the Medication Guide and Prescribing Information included in the package.*
Ahp90221
Image (B28dd501 1384 4376 Be15 Ce15c0d22439 01)
Figure 1 (B28dd501 1384 4376 Be15 Ce15c0d22439 02)
This text appears to show data related to FEV (Forced Expiratory Volume) measurements in liters. The table compares the number of subjects in two groups (Sirolimus and Placebo) and their respective percentages of responses at certain levels of FEV. The Sirolimus group shows responses of 38%, 21%, and 14%, while the Placebo group shows responses of 43%, 40%, 2%, 39%, 3%, 2%, and 18%.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
